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Key points: To tackle antimicrobial resistance, we need first to quantify and map its drivers. In this 
viewpoint, we propose a detail three key action areas that desperately require systems mapping 
approach to do this, attention: the mapping of sources and transmission routessupported by 
comprehensive, data collection and novel quantification analysis..  
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Abstract 
 
The global threat of antimicrobial resistance (AMR) has arisen through a network of complex 
interacting factors. Many different sources and transmission pathways contribute to the ever-growing 
burden of AMR in our clinical settings. The lack of data on these mechanisms and the relative 
importance of different factors causing the emergence and spread of AMR hampers our global efforts 
to effectively manage the risks. Importantly, we have little quantitative knowledge on the relative 
contributions of these sources and are likely to be targeting our interventions suboptimally as a result. 
Here we propose a systems mapping approach three major actions to address the urgent need for 
reliable and timely data in order to strengthen the response to AMR.  
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Introduction 
Current situation 
Antimicrobial resistance (AMR) “poses a profound threat to human health”.[1] Policy makers, 
researchers and funders have stressed the importance of developing new diagnostics and medicines, 
improving surveillance and defining appropriate antimicrobial use to counter this global threat.[2, 3] 
Concerns on AMR are now a regular feature in the popular media, creating an impetus for politicians 
and policy makers to decisively address the risks. Yet, an important ingredient of an effective 
response has been largely overlooked: reliable and timely data to map and determine the relative 
contributions of AMR sources and transmission routes to overall AMR risk. Importantly, for example, 
we do not know what proportion of patients with infections with resistant pathogens acquired that 
pathogen from direct person to person transmission versus through the consumption of contaminated 
meat. 
The primary drivers of AMR are thought to include suboptimal use of antimicrobial 
compounds agents in hospitals, the community and agriculture, as well as background exposure in 
waste water, soils and other environmental reservoirs.[3-8] However, the extent to which these 
sources contribute to the development, emergence and spread of AMR is not yet quantified.[9] 
Without this critical, system-wide knowledge it is impossible to effectively optimise and target 
interventions.  
The selection process that produces AMR occurs through exposure to antimicrobials. 
However, the relationship between the extent of antimicrobial exposure and the amount rate of AMR 
selection has not been quantified.[10, 11] The appearance of AMR strains in clinical environments 
will may [a1]also be dependent on their transmission from source environments. Hence, both the 
sources and transmission pathways of AMR need to be identified and mapped to understand the flow 
of AMR to frontline clinical interfaces. For example, high antimicrobial use occurs in the agricultural 
environment, but we do not know how frequently this use leads to selection of AMR, if there is a 
dose-response relationship, or the nature and magnitude of AMR transmission from this environment 
into clinical settings.[12] The overall contribution of agricultural antimicrobial use to clinical AMR 
risk thus remains unknown. This lack of a quantified risk means that interventions to reduce antibiotic 
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prescribing in agriculture, whilst logical, will have an underterminedundetermined impact on the 
levels of infection with AMR pathogens in clinical settings. Moreover, the lack of knowledge also 
hampers advocacy for any intervention in this setting.  
Emerging infectious disease outbreaks, such as Ebola, and more recently the Zika virus in 
Brazil, demonstrate how even rare events can have catastrophic consequences for public health by 
overwhelming health systems that are typically designed to manage endemic, consistent or predictable 
health pressures. AMR poses similar risks to health systems.[1] While multiply resistant microbial 
strains are likely to be rare in comparison to resistant strains that remain treatable by available and 
alternative compounds, the consequences of an untreatable strain overwhelming our last lines of 
defence would be great. A key point here is that moving between antibiotic treatments is not as simple 
as changing oral prescriptions. Susceptibilities are likely to be to older antibiotics or to those less 
frequently used, but this reduced use is often for a reason. These alternative compounds often have 
more serious side effects or are more difficult to prescribe (e.g. intravenously). As any new resistance 
could ultimately be the last one required for a pan-resistant strain, identifying AMR selection hotspots 
is critical for stemming AMR risks at the most relevant sources, while quantitative knowledge on 
transmission networks is central to interrupting AMR spread. With ever limited resources, a systems 
approach to both a ranking of the importance of these hotspots, and the transmission pathways is 
required for prioritisation of action or control method optimisation.  
The hotspots and their relative contributions to selection and transmission are likely to vary 
by setting.[7] For example, countries will have different levels of direct antimicrobial exposure due to 
varying degrees [13]of use of antimicrobials in agriculture [13]. Indirect factors will also vary, such as 
levels of sanitation, density of antimicrobial-producing pharmaceutical companies and political will to 
tackle AMR (for example with the formation of national action plans [14, 15]). Until this systems 
variation (both between and within countries) and then the fundamental information on the relative 
contribution of each of these factors is known, it will not beFor example, in Australia high 
antimicrobial use in both community and hospital settings may select directly for resistance in 
patients, requiring no importation from external sources to result in healthcare issues,[13] while in 
India poor sanitation may facilitate the transmission of AMR in communities otherwise unexposed to 
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antimicrobials.[3, 14] Hence, improving access to sanitation may have a bigger relative impact on 
reducing the risk of AMR in India compared to Australia, while targeting antimicrobial prescribing 
may have a relatively greater effect in Australia than India. In the absence of such data, however, it is 
not possible to develop policies or efficiently allocate resources to develop targeted and context-
specific interventions across for multiple settings. 
 To date, most AMR research has focused on evaluation of interventions (aimed at infection 
control for prevention and for reducing antimicrobial usestewardship)[16], surveillance, risk factor 
analysis and strain characterisation (including identification of mechanisms of resistance and genetic 
determinants of AMR). Research on surveillance of resistance patterns suggest strong spatial variation 
in AMR [16]and in the use of antimicrobials. (e.g., in animal based food production systems).[17-19]  
For instance, the majority of antibiotic prescriptions in the UK are in the community and yet the most 
clinically serious AMR infections are often hospital acquired.[20] Does this mean that reducing 
prescrtiptions in primary care would have a smaller little effect on levels of infection with resistant 
pathogens than reducing prescriptions in hospitals? Or is it the key that drives colonisation with and 
selection of AMR, with subsequent opportunitesopportunities for endogenous infection once a host 
becomes immunocompromised i.e. hospitalised? Although links have been found across 
environments, for example between outpatient prescribing and hospital resistance levels [21-
23]{Vernaz, 201{Hicks, 2011 #32}{Gallini, 2010 #31}1 #33}, fFew studies have explored their what 
the relative contributions contributing environments are to these differences and no studies, to our 
knowledge, have established which transmission routes contribute the most to the most serious 
infections with resistant patheogenspathogens in clinical settings. For example, although a link 
between travel and AMR spread has been established [24], and studies have revealed key genetic 
factors underlying transmission, no studies have quantified the relative contribution of travel to AMR 
in comparison to other factors.   
 
Future action areas 
Based on these observations, we believe that there is a major gap in our understanding of 
AMR that requires a revolution in the analysis and quantification of the sources and transmission 
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routes of AMR. To tackle this, we propose that a comprehensive systems mapping approach is 
needed, with the support of data collection and modelling. The key action points are summarised in 
Box 1. three interdependent actions.  
First, there is a need to establish a ‘global systems map’ of AMR selection sources and 
transmission routes. Collaborative action by the global public health community is necessary to 
determine the relative contributions of sources and transmission routes to AMR[25, 26], including the 
most relevant environments and drivers at local, national and global levels (Figure 1). While there are 
current efforts to identify drivers of AMR in different environments,[1, 27] a comprehensive approach 
is lacking.[3] Research is needed to systematically map the complex network of environments and 
locations of selection, as well as quantifying the interplay of pathways that affect transmission (Figure 
1). The formation of a ‘global systems map’ requires his step requires the international collaboration 
to: (1) construct a flexible map framework, perhaps within a specifically designed web-based 
platform, that allows for easy comparison and modification by individual countries, (2) develop a 
shared language of specific definitions for AMR ‘drivers’, ‘risk factors’ and ‘transmission pathways’, 
as well as for labelling environments (‘sewage’ or ‘waste water’), (3) use the framework to build 
consensus around the systems involved in AMR, how they differ by setting and to continually update 
the systems map through conversations with all stakeholders, from patient groups to international 
health organisations. community to come together to  
 collate the “map” to provide a comprehensive guide for data collection.  
Second, uUsing the above map, there is then, secondly, a need to collect and collate data in order to 
quantify relative contributions to AMR and to populate the ‘global systems map’ with quantitative 
information. Currently, there is no global database that collates information on the occurrence of 
antimicrobial use or AMR.[25] However, building on While the first AMR global surveillance report 
(was published in 2014 ,[1]) as well as existing national level clinical datasets,[18, 28] the WHO has 
now launched the Global Antimicrobial Resistance Surveillance System (GLASS) to fulfil one of the 
5 strategic objectives of the WHO action plan on AMR.[29] This will collect and then report AMR 
rates aggregated at the national level, giving information on level of resistance within clinical isolates. 
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This global endeavour is supported by government and NGO initiatives such as the Fleming Fund in 
the UK and the Bill and Melinda Gates Foundation.  
To populate the ‘global systems map’ critically requires countries to support these actions, but 
also requires further resistance data; for example, resistance levels within samples from agriculture, 
water and soil. For the identification and quantification of transmission pathways, a Similarly 
comparison of isolates between settings can use using genetic distance to infer can help identify 
overlapping sources.[19, 30, 31] The map also requires systems level information on the places where 
antimicrobial are prescribed and transmission pathways; for example, the amount of intensive farming 
(such as has been mapped globally in [32]) and how much antimicrobials are used where (for some 
drugs, this has been done globally at the national level [17]). A comparison of the existing resistance 
environment, using for example composite measures such as the Drug Resistance Index [33], can then 
be complemented by a comparison of underlying AMR drivers and transmission routes. This stage 
requires national organisations to (1) collate their new and existing datasets to inform all stages of the 
‘global systems map’ for AMR, (2) compare and contrast between countries to determine data gaps 
and potential ways for data collection to be effectively performed, perhaps with the inclusion of 
sentinel sites, (3) use the ‘global systems map’ as a visualisation tool to identify new potential areas of 
AMR emergence and areas where effective control has been achieved.  
  a lack of an established surveillance system hampers efforts to systematically gather such 
data.[29] Collating and analysing existing datasets, such as those on intensive farming areas[30] and 
existing national level clinical datasets,[18, 31] could help to identify areas of AMR emergence and 
areas where effective control has been achieved[GK2]. Similarly comparison of isolates between 
settings can use genetic distance to infer overlapping sources.[19, 32, 33] Building on existing work 
to collate and analyse data from different selective environments,[13, 17]  the next steps are to 
quantify selection sources and transmission routes, but also to determine data gaps that need 
addressing.  
Third, quantification of selection sources and transmission routes will require novel analytic 
approaches to measure source contributions, to establish relative importance of transmission pathways 
and to predict the likely impacts of interventions. These analytic approaches will need to combine 
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cutting edge statistical methods as well as mathematical and systems dynamics modelling, the 
potential contribution of which to global health is outlined in .[34]. For example, mathematical 
models are needed that capture the movement of AMR pathogens between environments rather than 
only the dynamics within a single setting (such as a hospital ward). Currently, many mathematical 
models are only of the transmission of resistant pathogens between individuals within a hospital[35], 
with some, often fixed, incoming rate of pre-colonisation with resistant pathogens. Only by allowing 
the latter rate to vary, by including a dynamic modelling of the processes in external settings can our 
understanding of the relative contribution of selection and transmission in different settings be 
determined.  
 Statistical methods, such as multi-level modelling, will need to be adapted to consider the 
complexities of time-dependent bias in AMR acquisition and different risk factor profiles. The 
interacting nature of selection and transmission requires adjustment for correlations between 
statistical hierarchies that may require novel statistical formulations. This is important, as to reveal the 
relative contributions of different settings, correction for interaction relationships are needed to 
remove bias from risk profiles.  
The resulting models should holistically map and integrate complex pathways and 
transmission systems, and account for stochastic or random behaviour of AMR spread, such as 
outbreaks and introductions of AMR strains or genetic determinants. This would enable the models to 
test for the effects of potential interventions on AMR emergence and control by considering the 
system as a whole.[2] Importantly, this would allow for a “One Health” approach to AMR 
understanding and intervention optimisation. This stage requires the academic community, supported 
by the public health and policy community alongside cross-sectoral agencies, to work with the ‘global 
systems map’ to develop new quantitative tools that can (1) integrate information from a range of 
sources, (2) account for multiple environments, complex correlations and stochastic behaviour, (3) 
predict the impact and hence compare interventions.  
With these systems modelling tools, and given sufficient data, the relative contribution of 
each source and transmission pathway to AMR can then be quantified (Box 1). Only from such 
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quantification can come the mathematical modelling predictions as to where to optimally target 
interventions for control.  
 
Conclusion 
A systems approach that enables comprehensive mapping of selection sources and 
transmission pathways in settings at a sub-national, national and global level will enable more holistic 
exploration and optimisation of policies and interventions designed to control AMR. Collation of data 
and targeted generation of hypotheses, underpinned by systems modelling approaches will help 
identify more effective combinations of interventions across multiple settings (e.g., countries, sectors) 
that could efficiently combat the profound global threat that AMR poses to human health and welfare.  
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Figure 
 
 
Figure 1: Example factors influencing AMR selection and transmission pathways that 
require quantification for a more effective and efficient global response. 
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Box 1: Stages required for determination of the relative contributions of different sources and 
transmission routes to AMR.  
 
What are the relative contributions of  
different sources and transmission routes to AMR? 
 
1. Formation of a ‘global systems map’  
Requires international collaboration to:  
1.1 construct a flexible map framework  
1.2 develop a shared language of specific definitions  
1.3 use the framework to build consensus around the systems involved in AMR 
2. Data collation 
Requires individual countries to:  
2.1 collate their new and existing datasets  
2.2 compare and contrast between countries to determine data gaps  
2.3 use the ‘global systems map’ as a visualisation tool for AMR control  
3. Modelling analysis 
Requires a supported the academic community to develop quantitative tools that can:  
3.1 integrate information from a range of sources  
3.2 account for multiple environments and correlations, and stochastic behaviour 
3.3 make predictions around AMR burden   
